Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clofenamide
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Clofenamide is a benzenedisulfonamide-based small molecule diuretic that acts as a carbonic anhydrase inhibitor. By inhibiting carbonic anhydrase in the proximal convoluted tubule of the kidney, it reduces sodium and bicarbonate reabsorption, leading to increased excretion of sodium, bicarbonate, and water (diuresis). It is classified as a low-ceiling sulfonamide diuretic and has been used for its diuretic effects in cardiovascular conditions[1][8][5].
- Brand names
- AqueduxHaflutanSalcoSaltronSoluran
- Other names
- diumide4-chloro-m-benzenedisulfonamideAponiereClofenamidumDiuretic 2822Diuretic2822Diuretic-2822EleklinFrictanSalzenIndigatinMacashiDS (pharmaceutical)
02
Targets
CA (Carbonic anhydrase)
Beyond the preview
Go deeper on clofenamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clofenamide.